Impacts
- 6 results
Search results
-
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02). N Engl J Med 362(14): 1273-81
Juan Valle (Corresponding participant)
Impact: Health impacts, Societal impacts
-
Defining immunotherapy in combination with chemotherapy as first-line treatment of patients with advanced biliary tract cancer (durvalumab)
Valle, J. (Corresponding participant) & Mcnamara, M. (Participant)
Impact: Health and wellbeing
-
Defining the role of second-line chemotherapy for patients with advanced / inoperable biliary tract cancer (FOLFOX (oxaliplatin/5FU))
Juan Valle (Corresponding participant)
Impact: Health and wellbeing
-
Establishing a standard of care treatment for biliary tract cancer patients following surgery (capecitabine)
Valle, J. (Corresponding participant)
Impact: Health and wellbeing
-
Improved treatment option for patients with previously treated IDH-1 mutated cholangiocarcinoma (bile duct cancer) (Ivosidenib)
Juan Valle (Corresponding participant)
Impact: Health and wellbeing
-
Seeking better treatments for patients with intrahepatic cholangiocarcinoma (iCCA) and FGFR2 gene rearrangement (futibatinib)
Juan Valle (Corresponding participant)
Impact: Health and wellbeing